Stay updated with breaking news from பால் ஃபிநிகெந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Harvard endowment executives earn $31 million in 2019 Harvard Management CEO Narvekar paid over $6.25 million Nirmal P. Narv Narvekar Harvard University, Cambridge, Mass., paid its top six endowment officials $31 million in 2019, according to a news release Friday. Nirmal P. Narv Narvekar, president and CEO of Harvard Management Co., which oversees the university s $41.9 billion endowment, took home more than $6.25 million in 2019. Although Sanjeev Daga, HMC s chief operating officer, made nearly $5 million in compensation for 2019, he was reimbursed compensation that he forfeited when he left Columbia University s investment office to join HMC in February 2019, which brought what he received for the year to more than $6.26 million. ....
Braithwaite, Kelly, Reid Keep Leads In Final Evanston Vote Count patch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from patch.com Daily Mail and Mail on Sunday newspapers.
VISIT WEXFORD READY TO DEAL WITH WHATEVER TOURISM IS ALLOWED THIS SUMMER The new chairperson of Visit Wexford says they’re ready to make the most of whatever summer we have. Paul Finnegan of the Ashdown Park Hotel has taken on the role and knows tourism is still a great unknown in the time of Covid 19. His hotel have had to re-arrange bookings for guests this summer due to the changing nature of the restrictions. Speaking on the Morning Mix, Paul says even though this year is still up in the air, tourism will be a major industry for County Wexford in the years to come: ....
Share this article Share this article SAN DIEGO, March 12, 2021 /PRNewswire/ Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b/2 study to prevent progression to severe organ toxicities in lymphoma subjects undergoing curative high-dose consolidation therapy with autologous hematopoietic cell transplantation (HDT-AHCT). Our investigators and Angiocrine are honored to be selected by EBMT to present at its annual meeting this March, commented Paul Finnegan, MD, Angiocrine CEO. We look forward to Dr. Caroline Mulroney s presentation of AB-205 s efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication. ....